Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

BACKGROUND: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed to evaluate the efficacy and safety of ramucirumab in Chine...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, Qin, Shukui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562926/
https://www.ncbi.nlm.nih.gov/pubmed/36247923
http://dx.doi.org/10.1016/j.eclinm.2022.101679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562926/
https://www.ncbi.nlm.nih.gov/pubmed/36247923
http://dx.doi.org/10.1016/j.eclinm.2022.101679

Ejemplares similares